ArticleJCI insight2020
Reciprocal immune enhancement of dengue and Zika virus infection in human skin.
Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- A Global Perspective on the Emerging Threat of Zika and Dengue Co-infection.PLoS neglected tropical diseases · 2026Article
- Interplay between innate immune cells and inflammatory mediators in dengue infection: an evolving therapeutic paradigm.Expert reviews in molecular medicine · 2025Review
- Advancing dengue vaccine development: Challenges, innovations, and the path toward global protection.Pediatric investigation · 2025Review
- Localized Inflammation in Dengue Vaccine-Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome.The Journal of investigative dermatology · 2025Article
- Genetic ancestry shapes dengue virus infection in human skin explants.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.The Lancet. Infectious diseases · 2025Review
- Article
- The Dynamic Relationship between Dengue Virus and the Human Cutaneous Innate Immune Response.Viruses · 2024Review
- A mosquito salivary protein-driven influx of myeloid cells facilitates flavivirus transmission.The EMBO journal · 2024Article
- Influence of previous Zika virus infection on acute dengue episode.PLoS neglected tropical diseases · 2023Article
- The significance of mosquito saliva in arbovirus transmission and pathogenesis in the vertebrate host.One health (Amsterdam, Netherlands) · 2023Article
- Replication in the presence of dengue convalescent serum impacts Zika virus neutralization sensitivity and fitness.Frontiers in cellular and infection microbiology · 2023Article
- Novel Therapeutic Nutrients Molecules That Protect against Zika Virus Infection with a Special Note on Palmitoleate.Nutrients · 2022Review
- A Human Skin Model for Assessing Arboviral Infections.JID innovations : skin science from molecules to population health · 2022Article
- Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model.Pathogens (Basel, Switzerland) · 2022Review
- Multiple Salivary Proteins fromViruses · 2022Article
- Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity.The Lancet. Infectious diseases · 2021Review
- Lying in wait: the resurgence of dengue virus after the Zika epidemic in Brazil.Nature communications · 2021Article
- Hide and Seek: The Interplay Between Zika Virus and the Host Immune Response.Frontiers in immunology · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
Dengue virus (DENV) and Zika virus (ZIKV) are closely related mosquito-borne flaviviruses that co-circulate in tropical regions and constitute major threats to global human health. Whether preexisting immunity to one virus affects disease caused by the other during primary or secondary infections is unknown but is critical in preparing for future outbreaks and predicting vaccine safety. Using a human skin explant model, we show that DENV-3 immune sera increased recruitment and infection of Langerhans cells, macrophages, and dermal dendritic cells following inoculation with DENV-2 or ZIKV. Similarly, ZIKV immune sera enhanced infection with DENV-2. Immune sera increased migration of infected Langerhans cells to the dermis and emigration of infected cells out of skin. Heterotypic immune sera increased viral RNA in the dermis almost 10-fold and reduced the amount of virus required to infect a majority of myeloid cells by 100- to 1000-fold. Enhancement was associated with cross-reactive IgG and induction of IL-10 expression and was mediated by both CD32 and CD64 Fcγ receptors. These findings reveal that preexisting heterotypic immunity greatly enhances DENV and ZIKV infection, replication, and spread in human skin. This relevant tissue model will be valuable in assessing the efficacy and risk of dengue and Zika vaccines in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.